Loading clinical trials...

NOT_YET_RECRUITINGNA

Billroth II With Braun Anastomosis After Radical Distal Gastrectomy for Gastric Cancer

Billroth II With Braun Anastomosis Versus Billroth II Anastomosis After Radical Distal Gastrectomy With D2 Lymphadenectomy for Gastric Cancer: a Randomized Controlled Trial

NCT06229197•Sichuan University

View on ClinicalTrials.gov

Summary

The primary aim of this trial is to rigorously evaluate the comparative benefits and potential risks associated with Billroth II reconstruction with Braun anastomosis versus Billroth II reconstruction alone following distal gastrectomy with D2 lymphadenectomy in patients diagnosed with gastric cancer. This assessment focuses on delineating the therapeutic efficacy, safety profile, and overall clinical outcomes of these two surgical approaches in treating this condition.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Histologically proven stage I-III gastric cancer, evaluated as radically resectable
•2. No synchronous or metachronous cancers
•3. Patients have signed informed consent forms
•4. Age 18-80 years old
•5. No malfunction of cardio-pulmonary, liver, and kidney, ECOG score 0-1
•6. No emergency surgery needed

Exclusion Criteria

•Patients will be excluded according to the following criteria:
•1. Pregnant or lactating women
•2. Distant metastasis to the liver, lung, bone, supraclavicular lymph nodes, pelvic, or ovarian species and peritoneal dissemination
•3. Ascites or cachexia
•4. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, poorly controlled hypertension or diabetes
•5. Participation in other clinical trials 4 weeks before the enrollment of this trial or still participating in other trials
•6. Mental illness
•7. Surgical history whose influence has not been eliminated
•8. History of another gastric or esophageal malignancy, including stromal tumor, sarcoma, lymphoma, and carcinoid
•9. Active infection with a fever of over 38°C
+2 more criteria

Key Dates

Start Date

February 1, 2024

Primary Completion Date

December 31, 2026

Completion Date

December 31, 2027

Last Updated

January 29, 2024

Enrollment

176

ESTIMATED participants

Conditions

Gastric CancerSurgeryAnastomosisGastrostomy

Interventions

Billroth II reconstruction

PROCEDURE

Braun Anastomosis

PROCEDURE

Contacts

Zhaolun Cai, MD, PhD

CONTACT

+86-028-85423610 caizhaolun@foxmail.com

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITING

Evaluation of Resection Techniques for Pancreatic Tumors

NCT05128890

SurgeryLiver Tumor+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 29, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Billroth II With Braun Anastomosis After Radical Distal Gastrectomy for Gastric Cancer

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Evaluation of Resection Techniques for Pancreatic Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Resilience and Equity in Aging, Cancer, and Health (REACH)

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma